Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

2022/05/04 by Noelle V. Frey · 21 citations
Medicine · #CAR-T cell therapy research

paper · pdf · doi:10.1182/blood.2021014892

Abstract

In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T-cell product to receive approval from the Food and Drug Administration to treat adults with relapsed and refractory B-cell acute lymphoblastic leukemia. The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.

Citations

• KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Cited by

• CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. [europepmc]
• Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. [europepmc]
• Molecular and therapeutic effect of CRISPR in treating cancer. [europepmc]
• Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease. [europepmc]
• T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. [europepmc]
• Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. [europepmc]
• Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. [europepmc]
• Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display. [europepmc]
• CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia. [europepmc]
• Differential protein-protein interactions underlie signaling mediated by the TCR and a 4-1BB domain-containing CAR. [europepmc]
• Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope? [europepmc]
• Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy. [europepmc]
• Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. [europepmc]
• Allogeneic CAR-T cells for cancer immunotherapy. [europepmc]
• Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. [europepmc]
• Clinical development of allogeneic chimeric antigen receptor αβ-T cells. [europepmc]
• CAR-T cell therapy for cancer: current challenges and future directions. [europepmc]
• Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art. [europepmc]
• CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapy. [europepmc]
• Precision immunotherapy with CAR-T cells in pediatric B-cell acute lymphoblastic leukemia: advances and unanswered challenges. [europepmc]
• How to Change the Role of Allogeneic Hematopoietic Cell Transplantation in Adults with B-Cell Acute Lymphoblastic Leukemia. [europepmc]

Related

• KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
• Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia
• The evolving therapeutic revolution in adult acute lymphoblastic leukemia
• Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
• CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?